StockData
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC) stock

ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.37−0.01 (-3.62%)

Close on Nov 18, 2026Market cap $7.20MP/E –Yield –

Ensysce Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Ensysce Biosciences's revenue for the twelve months ending Jun 30, 2026 was $4.50M, down 39.3% year over year. For fiscal 2025 it was $5.07M, down 2.8% from the year before. The highest annual figure on record is $5.21M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.07M-2.8%
FY2024Dec 31, 2024$5.21M+133.6%
FY2023Dec 31, 2023$2.23M-11.6%
FY2022Dec 31, 2022$2.52M-28.5%
FY2021Dec 31, 2021$3.53M-10.2%
FY2020Dec 31, 2020$3.93M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.16M-15.1%
Q1 FY2026Mar 31, 2026$961.00K-27.2%
Q4 FY2025Dec 31, 2025$1.88M+44.4%
Q3 FY2025Sep 30, 2025$493.10K-85.6%
Q2 FY2025Jun 30, 2025$1.37M+654.4%
Q1 FY2025Mar 31, 2025$1.32M+331.7%
Q4 FY2024Dec 31, 2024$1.30M+153.1%
Q3 FY2024Sep 30, 2024$3.42M+685.3%
Q2 FY2024Jun 30, 2024$181.80K-62.9%
Q1 FY2024Mar 31, 2024$305.72K-61.3%
Q4 FY2023Dec 31, 2023$515.03K-64.1%
Q3 FY2023Sep 30, 2023$435.38K+55.9%
Q2 FY2023Jun 30, 2023$490.47K+136.4%
Q1 FY2023Mar 31, 2023$789.64K+30.9%
Q4 FY2022Dec 31, 2022$1.43M-12.3%
Q3 FY2022Sep 30, 2022$279.35K-76.7%
Q2 FY2022Jun 30, 2022$207.47K-53.3%
Q1 FY2022Mar 31, 2022$603.10K+140.7%
Q4 FY2021Dec 31, 2021$1.64M+292.6%
Q3 FY2021Sep 30, 2021$1.20M+45.1%
Q2 FY2021Jun 30, 2021$444.52K-75.6%
Q1 FY2021Mar 31, 2021$250.58K–
Q4 FY2020Dec 31, 2020$416.49K–
Q3 FY2020Sep 30, 2020$827.64K–
Q2 FY2020Jun 30, 2020$1.82M–

More Ensysce Biosciences figures

See a number that looks wrong?